EPM
CRXTW

Equitec Proprietary Markets’s Clarus Therapeutics Holdings, Inc. Warrants CRXTW Stock Holding History

Equitec Proprietary Markets’s Portfolio CRXTW Stock Details CRXTW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-34,555
Closed -$10K – 459
2021
Q4 		$10K Hold
34,555
– – ﹤0.01% 369
2021
Q3 		$26K Buy
34,555
+4,555
+15% +$3.43K ﹤0.01% 168
2021
Q2 		$23K Buy
+30,000
New +$18.8K 0.01% 208

Other funds holding CRXTW

LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $21.5B AUM 81.81% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
BI
Bulldog Investors Saddle Brook, New Jersey $455M AUM 2.3% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Equitec Proprietary Markets's CRXTW Position: Q1 2022 in Review

Equitec Proprietary Markets sold out of Clarus Therapeutics Holdings, Inc. Warrants (CRXTW) in Q1 2022, closing a stake of 34,555 shares — an estimated $10K sold.

Equitec Proprietary Markets first reported a position in CRXTW in Q2 2021 and held it in 3 quarters. The position peaked at $26K in Q3 2021. 16 funds tracked by Wall St. Rank hold CRXTW as of Q1 2022.

  • Equitec Proprietary Markets reported no remaining Clarus Therapeutics Holdings, Inc. Warrants position as of Q1 2022 after selling out during the quarter.
  • Equitec Proprietary Markets sold 34,555 Clarus Therapeutics Holdings, Inc. Warrants shares in Q1 2022, an estimated $10K.
  • Equitec Proprietary Markets first reported a position in Clarus Therapeutics Holdings, Inc. Warrants in Q2 2021 and held it in 3 quarters.
  • Equitec Proprietary Markets's Clarus Therapeutics Holdings, Inc. Warrants position peaked at $26K in Q3 2021.
  • 16 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Warrants as of Q1 2022.

Based on Equitec Proprietary Markets's 13F filing for Q1 2022, filed 22 Apr 2022.